🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

18,99 USD

Máx. histórico

178,74

2143 días

Split 1:6 del 12/07/2012

Caída desde máximo

-89,38%

Rango 52 semanas

14,68 – 24,68

Variación hoy

+2,43%

Cierre anterior

18,54

Rango de hoy

18,52 – 19,26

Volumen hoy

1.328.200

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,43%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 23 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
03/12/2001 56,82 57,30 55,32 56,82 -0,73% 3,48% 20.233
30/11/2001 55,80 57,30 55,50 57,24 +0,95% 3,23% 14.917
29/11/2001 56,40 57,30 55,80 56,70 +0,85% 2,66% 23.817
28/11/2001 53,94 56,22 51,78 56,22 +4,11% 8,23% 17.300
27/11/2001 54,60 56,10 51,60 54,00 +6,76% 8,24% 18.883
26/11/2001 51,30 51,90 50,10 50,58 -1,52% 3,51% 6.983
23/11/2001 51,30 51,90 50,70 51,36 +0,12% 2,34% 6.717
21/11/2001 48,48 51,54 47,70 51,30 +5,56% 7,92% 22.800
20/11/2001 50,70 51,30 48,42 48,60 -4,71% 5,68% 17.250
19/11/2001 50,04 51,30 49,92 51,00 +3,03% 2,76% 10.233
16/11/2001 52,50 52,56 45,96 49,50 -7,20% 12,57% 28.183
15/11/2001 55,20 55,20 51,96 53,34 -2,84% 5,87% 16.600
14/11/2001 56,40 56,40 52,86 54,90 -1,08% 6,28% 33.933
13/11/2001 55,20 56,70 54,96 55,50 -2,22% 3,15% 13.717
12/11/2001 59,10 59,10 52,98 56,76 -3,07% 10,36% 27.800
09/11/2001 56,10 59,10 54,60 58,56 +3,61% 8,02% 39.300
08/11/2001 57,60 58,02 55,80 56,52 +0,11% 3,85% 31.050
07/11/2001 56,40 57,00 55,56 56,46 +1,18% 2,55% 39.600
06/11/2001 52,80 56,04 52,80 55,80 +6,41% 6,14% 36.983
05/11/2001 51,48 52,50 49,50 52,44 +1,51% 5,83% 55.233
02/11/2001 50,76 53,64 49,44 51,66 -1,60% 8,27% 47.633
01/11/2001 46,80 53,34 46,50 52,50 +13,64% 14,62% 78.233
31/10/2001 43,50 46,20 43,20 46,20 +6,35% 6,90% 36.450
30/10/2001 43,50 43,80 42,60 43,44 -0,14% 2,76% 6.950
29/10/2001 42,90 44,40 42,90 43,50 -1,36% 3,50% 6.533
26/10/2001 43,20 44,10 42,72 44,10 +2,08% 3,19% 9.183
25/10/2001 44,10 44,10 41,40 43,20 -2,70% 6,12% 10.583
24/10/2001 42,36 44,64 42,36 44,40 +3,21% 5,38% 11.617
23/10/2001 43,20 43,50 42,60 43,02 -0,55% 2,08% 5.233
22/10/2001 43,44 43,44 42,30 43,26 -1,90% 2,62% 8.250